Evidencia

Tablas de evidencias

Esta tabla es un resumen del análisis reportado en una Respuesta Clínica Cochrane que se centra en la pregunta clínica más importante antes mencionada.


La confianza en las evidencias es alta o moderada a alta cuando se ha realizado el GRADE y la intervención es más eficaz/beneficiosa que la comparación para los principales resultados.


Población:Adultos con EPOC de moderada a grave

Intervención:Umeclidinio (una vez al día mediante un inhalador de polvo seco durante 12-52 semanas)

Comparación:Placebo

ResultadoEficacia (clasificación BMJ)?Confianza en las evidencias (GRADE)?

Número de participantes con exacerbaciones que requieren corticosteroides, antibióticos o ambos a las 52 semanas

Favorece una intervención

Alto

Calidad de vida a las 24-52 semanas (medida por el Cuestionario Respiratorio de St George [SGRQ])

Favorece una intervención

Moderada

Número de participantes con ingresos hospitalarios por exacerbación de la EPOC a las 52 semanas (medido por el Índice de Disnea Transitoria [IDT])

No hay diferencias estadísticamente significativas

Bajo

Mejoría en los síntomas a las 24 semanas

Favorece una intervención

Alto

Función pulmonar a las 4-52 semanas

Favorece una intervención

Alto

Eventos adversos graves no fatales

No hay diferencias estadísticamente significativas

Moderada

Eventos adversos

No hay diferencias estadísticamente significativas

Moderada

Esta tabla de evidencias está relacionada con la/s sección/es siguiente/s:

Respuestas clínicas Cochrane

  • What are the effects of integrated disease management (IDM) interventions for people with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • How does umeclidinium bromide compare with placebo for people with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • How does long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) compare with LABA plus inhaled corticosteroid (ICS) for people with stable chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • How does tiotropium compare with ipratropium bromide for people with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • How does a combined inhaler with once‐daily long‐acting beta2‐agonist (LABA) plus a long‐acting muscarinic antagonist (LAMA) compare with placebo for adults with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • What are the longer-term (>6 months) effects of inhaled corticosteroids in people with stable chronic obstructive pulmonary disease?
    Show me the answer
  • What are the effects of long‐acting inhaled therapies for adults with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • In people with chronic obstructive pulmonary disease (COPD), what are the effects of combined corticosteroid and long-acting beta-agonist (LABA) in one inhaler versus LABA alone?
    Show me the answer
  • What are the effects of prophylactic antibiotics for people with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • What are the effects of influenza vaccine in people with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • For people with chronic bronchitis or chronic obstructive pulmonary disease, how do mucolytic agents compare with placebo?
    Show me the answer
  • What are the effects of pulmonary rehabilitation after exacerbation in people with chronic obstructive pulmonary disease?
    Show me the answer
  • How does bronchoscopic lung volume reduction compare with medical therapy in people with chronic obstructive pulmonary disease?
    Show me the answer
  • How do statins compare with placebo for people with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • How does combined aclidinium/formoterol compare with aclidinium or formoterol monotherapy for people with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • How does lung volume reduction surgery compare with usual medical care in people with diffuse emphysema?
    Show me the answer

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad